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THE TREATMENT OF BLADDER CANCER 
BY NEOTHRAMYCIN 
Masayuki TSUGAYA, Hiroto WASHIDA, Noriaki HIRAO, Yusuke 
HAcHIsuKA, Hiroshi SAKAGAMI and Yutaka IWASE 
From the Department of Urology. Anjo Kosei Hospital 
(Chief: Dr. H. Washida) 
Neothramycin (NTM), an anthramycin-group anticancer antibiotic, was used in the treat-
ment of superficial carcinoma of the bladder. 
NTM was instilled into the bladder in the following dosages. Ten mg NTM in 20 ml of 
sterile distilled water was given first, and increased to 40 mg in 2') ml. This procedure was 
performed every second week to twice a day. Recently, in 2 p"tients. the treatment has been 
combined with 20 mg NTM intravenous administration. 
In 4 of the II patients (36%) the tumors disappeared completely, while in 6 patientg (55 
%) there was partial di.appearance of more than 50% and in one patient (9%) there was no 
effect. Three of the patients had irritable bladder symptom (temporarily). 
NTM was concluded to be effective for superftcial carcinoma of the bladder. 
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Since the treatment of intravesical in-
stillation of thio-TEPA by Jones and 
SwinneyD, the method of topical che-
motherapy with several anti-cancer drugs 
for superficial bladder cancer have been 
reported and it is now an established me-
thod of anti-bladder cancer treatment. 
This paper presents a summary of the 
first experience in the treatment of blad-
der cancer by the intravesical instillation 
of neothramycin. Neothramycin, abbre-
viated NTM, is a new anti-cancer anti-
biotic that was isolated from the culture 
broth of streptomyces strain MC 916-C4-
HO~~ 11J~11H 1 
CH3 0 7 5 N 
6 4 3 
o h 2 
R2 R, 
by Umezawa et a1.2,3). It is structur-
ally similar to anthramycin, sibiromycin, 
tomaymycin etc. of the anthramycin 
group. The antibiotic contains almost 
equal amounts of neothramycin A andB. 
The molecular weight of NTM is 262.1 
(Fig. 1). DNA has been reported to be 
the chemoreceptor of NTM and its re-
action rate to be slower than that of other 
DNA-binding antibiotics, including an-
thramycin, tomaymycin, sibiromycin, 
adriamycin and actinomycin4 ,S). NTM 
inhibits biosynthesis of nucleic acid, 
particularly RNA synthesis at the cellular 
NTM A: R, =OH. R2 =H 
NTM B:R,=H. R2=OH 
Neothramycin A : (3 S. 1 faS)- 2. 3, 5, , 1 a-tetra hydro- 3, 8 -dihydroxy- 7-
methoxy- 5 -oxo- 1 H-pyrrolo[ 2, 1 -c] [ 1 , 4] benzodiazepine 
Neothramycin B : (3 R, 11 as)- 2, 3, 5,11 a-tetrahydro- 3, 8 -dihydroxy- 7-
metho*y- 5 -oxo-l H-pyrrolo [2, 1 -c] [ 1 , 4] benzQdiazepine 
Molecular weight: 262.1. 
Fig. I. Chemical structure of Neothramycin (NTM) 
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MATERIALS AND METHODS 
This study comprised 9 men and 2 wo-
men with superficial bladder cancer. The 
patients were between 55 and 87 years 
Table 1. Clinical data of 11 patients 






Grade of differentiation 
Grade I 5 
Grade n 6 
Table 2. Regimen of this study 
Dose of NTM Interval of insti Iistion 
10111i- Weekly (1 IW) 
20111i- Daily ( 1 10) 
40mg. 
4Omg. 
Twice. week. weekly (2-1/1-2w) 
or every other week 
Daily or 6 times a week (!/D) 
6'W 
40mg. Twice a day (2/0) 






old, with a mean of 72.7 years old. Tumor 
classification was performed with the aid 
of urethrocystoscopy, ultrasonography, 
cytologic evaluation of urine and histo-
logic study of transurethrally obtained 
biopsy specimens. Five patients had 
grade 1 tumors and 6 patients had grade 
2 tumors without evidence of invasion 
(pTa-pTlb). The tumors were smaller 
than a walnut (Table I). 
The instillation was first carried out 
with 10 mg of NTM in 20 ml sterile water 
once a week. As some favourable effects 
were observed in the examination of 
cystoscopy after the first course, the doses 
of NTM were increased up to 40 mg in 
20 ml sterile water. This procedure was 
performed from twice a day to every 
other week (Table 2). 
The absorption of NTM from the blad-
der mucosa was studied in 3 patients. 
The NTM solution which was prepared 
to make a concentration of 40 mg NTM 
per 20 ml was instilled for one hour by 
means of an indwelling catheter. 
RESULTS 
Table 3 shows the results. In 4 of the 
11 patients (36%), the tumors disappeared 
completely, while in 6 patients (55%) 
there was partial disappearance, and in 
one patient (9%) there was no effect. The 
response rate was 91 percent. 
Table 3. Clinical data and results of treatment 
Grade of Single or Dose of NTM 
Cases Age Sex Size (Interval of instillation) Result Side effect differentiation multiple [intravenous administration) 
1- K.V. 71 M Gl Thumb's head S 4OmgX21 (2/0) CR Frequency 
2, M.K. n M G2 Thumb's head M 40mgX21 (210) CR Frequency 
3, V.H. 75 F Gl Little·finger's S 4OmgX12 (6 /W) CR heed (20mgX 7) 
4. K.N. 56 M G2 Thumb's head M 4OmgX26 (6 IW) CR 
(20mgX 9) 
5, K.K. 61 M G2 Walnut large S 4OmgX14 (110) PR 
6, G.N. 84 M Gl Walnut large S 40mgX 6 (110) PR 
7, M.I. 87 M G2 Thumb's head S 4OmgX24 (6/W) PR 
8, M.M. 76 F G2 Bean large S 20mgXl0 (110) PR 
9, E.E. 55 M Gl Rice large M 10mgX 9 (1/Wl PR 40mgX21 (1/2W-2-3/W) 
10. U.V. 80 M G2 Little-finger's M 401IIgXl0(1 /1- 2W) PR Frequency h.ad 40mgX18 (6/w) 
11. K.O. 78 M Gl Pea large M 40lllgXl0 (l-2!W) NC 








Recurrence after treatment 




with TUR without TUR 
2 
2 3 2 
O~--~--~2~--~3~--~4~--~5----~6 
Hours 
Fig. 2. Serum concentration of NTM after 
absorption from bladder cavity 
Two of the 4 patients who became tu-
mor-free were treated by intravesical 
NTM 40 mg twice a day, and the others 
treated by intravesical NTM 40 mg 6 ti-
mes a week combined with intravenous 
administration of NTM 20 mg (Table 3). 
Three patients experienced irritable blad-
der symptoms temporarily. In 2 of them, 
the increasing frequency occurred dur-
ing treatment which was performed twice 
a day, and in the other the increasing fre-
quency occurred during treatment which 
was performed 6 times a week (Table 3). 
Two of the 4 patients who became 
tumor-free were still without recurrence 
after 6 and 9 months, respectively. In the 
others, recurrences occurred after 2 and 
4.5 months, respectively. In 4 of the 6 
patients whose tumors were reduced 50 % 
or more, TUR was performed after this 
treatment. In one of this group there 
was no recurrence after 16 months, but 
in 5 of these patients recurrences appeared 
after 2.5 to 7 months (mean of 4.4) 
(Table 4). 
Absorption studies were carried out in 
3 patients at a concentration of 40 mg 
NTM per 20 ml The maximum serum 
concentration of NTM was 74.9 ngjml, 
69.9 ngjml in 2 patients, respectively and 
less than 25 ngjml in the other patient 
(Fig. 2). 
CASE REPORTS 
Case I; A 76-year-old woman was ad-
mitted to our hospital with gross hema-
turia. Cystoscopic examination revealed 
papillary tumor in the right lateral wall. 
Bladder biopsy revealed transitional cell 
carcinoma of grade 2. Intravesical instil-
lation of NTM, 20 mg dissolved in 20 ml 
sterile distilled water was given daily for 
10 days. 
Fig. 3 shows the cystoscopical findings 
before and after treatment. The tumor 
was reduced to approximately half after 
treatment. 
Ultrasonographic view of the lower 
abdomen showed the tumor, measuring 
13 mm in height by 13 mm in diameter 
before treatment, and measuring 7 mm in 
height by 8 mm in diameter after treat-
ment (Fig. 4). 
Case 2; A 71-year-old man was hospi-
talized because of gross hematuria and 
Fig. 3. Cystoscopical findings before and 
after treatment in Case I 
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Fig. 4. Ultrasonographic views before and 
after treatment in Case I 
Fig. 5. C.,.stoscopical findings before and 
after treatment in Case 2 
Fig. 6. Ultrasonographic views before and 
after treatment in Case 2 
frequency. Cystoscopy revealed papillary 
tumor in the right lateral wall. Bladder 
biopsy revealed transitional cell carcinoma 
of grade 2. Intravesical instillation of 
NTM 40 mg in 20 ml sterile water was 
given twice a day for 21 times. 
Fig. 5 shows the cystoscopical findings 
before and after treatment the tumor 
has disappeared after treatment. 
Ultrasonographic view demonstrated a 
large tumor, measuring 21 mm in height 
by 31 mm in diameter before treatment. 
The tumor has disappeared after treat-
ment (Fig. 6). 
DISCUSSION 
Intravesical Thio-TEPA was first used 
to treat bladder cancer in 1961. Although 
intravesical Thio-TEPA was found to be 
effective, serious effects, chiefly myelosup-
pression, hindered its clinical application. 
The molecular weight of Thio-TEPA 
may be related inversely to the absorption 
rate. Yeates reported that molecular size 
determined absorption from the bladder 
and the substances absorbed from the 
bladder have molecular weights of under 
200]) The molecular weight of Thio-
TEPA is 189 and it should, therefore, be 
absorbed6) The molecular weight of 
NTM is 262. 1 and, therefore, it should 
not be absorbed. However, there is a 
little absorption of NTM from the blad-
der mucosa. Absorption studies were 
carried out in 3 patients at a concentra-
tion of 40 mg NTM per 20 ml of sterile 
water. The NTM solution was then in-
stilled for one hour by means of an in-
dwelling catheter. More than 74.9 ng/ml 
NTM was not found in the blood of 3 
patients. 
When NTM was administered intrave-
nously, gastro-intestinal disturbance such 
as nausea and vomiting were the most 
frequen t ad verse reactions 7). There 
was no severe toxicity to the liver, 
kidney, heart or central nervous system. 
There was, therefore, no systemic side 
effects due to absorption of NTM7). 
When NTM was administered intrave-
nously in rabbits, the highest levels were 
shown in the kidney and urinary bladder, 
which might have been due to urinary 
excretionS). We had experienced that 
the size of supraclavicular lymphonodi 
metastasis of bladder tumor was decreased 
by administration of NTM intravenously. 
Therefore, the effect of combined NTM 
given intravesically and intravenously was 
expected to be excellent compared with 
instillation alone. Complete regresslOn 
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was observed with the combination 
therapy in 2 patients. 
Three of the 11 patients had irritable 
bladder symptoms during treatment. All 
recovered, however, and bladder capacity 
gradually normalized one or two months 
after the instillation ceased. The absence 
of systemic and severe local side effects 
is an advantage in treatment with NTM. 
In the present study there was recur-
rence of bladder tumor in 2 of 4 patients 
who became tumor-free and in 3 of the 4 
patients who had partial regression after 
treatment as an adjuvant to transurethral 
resection. Our limited experience does 
not permit definite conclusions concerning 
the tumor-prophylactic effect of intrave-
sical NTM, but NTM seems to have little 
value as a prophylactic agent to prevent 
recurrences of bladder cancer. It is 
clear from our series of patients that 
NTM is at least as safe and effective as 
any other drugs which have been tried. 
We reported a summary of this paper 
at the 6th Congress of European Associa-
tion of Urology 1984. 
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とくである.初 回に はNTM10mgを 滅菌蒸留水
20mlに溶解させて膀胱内に注入 し,副作用がないた
め40mgに 増量した.投与間隔は2週 に1回 からは
じめ,1日2回 の膀胱内注入を行なった.最近の2例
*現:名古屋市立大学医学部泌尿器科学教室
に膀胱内注入療法に加えてNTM20mgの 経静脈性
全身投与の併用療法を試みた.
成績は11例中著効4例(36%),50%以上の縮小が
認められた有効6例(55%)で,無効1例(9%)で
あった.副 作用としては3症例に一過性の膀胱刺激症
状が認められた.
表在性膀胱癌の治療にはNTMが 有効な薬剤であ
ると考えられる.
